Can brain natriuretic peptide (BNP) be used as a screening tool in general practice?

Schaufelberger, Maria; Bergh, Claes‐Håkan; Caidahl, Kenneth; Eggertsen, Robert; Furenäs, Eva; Lindstedt, Göran; Nilsson, Thomas; Stefferud, Kari; Swedberg, Karl

doi:10.1080/02813430410006594

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the cost‐benefit of including the “at‐risk” patient into a heart failure program must be carefully analysed. It has been shown that screening a population with low prevalence of LVSD (<1%) is not cost‐effective [28–30] and yet these and other preliminary data have suggested that there may be cost‐benefits from screening higher‐risk populations for structural heart disease using BNP testing [31]. Prospective studies are clearly needed, to clarify the incremental clinical benefit of screening for and aggressively managing risk factors to prevent the development of heart failure.…”

Section: An Unproven Strategymentioning

confidence: 99%

Disease management programs for heart failure: Not just for the ‘sick’ heart failure population

McDonald

Conlon

Ledwidge

2007

European J of Heart Fail

View full text Add to dashboard Cite

The development of disease management programs has been a major advance in heart failure care, bringing about significant improvements for the heart failure population, with reduction in readmission, better use of guideline therapy and improved survival. However, at present, the majority of such programs focus their attention only on the sicker segment of this population, with little application of this important service to the broader heart failure population, where potentially benefits may be even more impressive. This has led to an imbalance in the care of patients with heart failure, where aspects of management such as regular structured review and education are preferentially given to the group at the later stages of the natural history of the syndrome. This paper argues for a far wider application of the disease management program concept in heart failure care so as to bring the benefits of specialist care, patient education and follow-up to patients at an earlier stage in the natural history of heart failure.

show abstract

Section: An Unproven Strategymentioning

confidence: 99%

Disease management programs for heart failure: Not just for the ‘sick’ heart failure population

McDonald

Conlon

Ledwidge

2007

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…The use of echocardiography, which is essential for a correct diagnosis, is still seldom used in primary healthcare [7]. Brain natriuretic peptide, which recently has been introduced as a specific marker for HF, is often not used in routine care [17,18]. Studies have shown that optimal treatment, according to guidelines, is seldom used, which might not be surprising when the diagnosis is often mainly based on clinical signs [19].…”

Section: Discussionmentioning

confidence: 99%